MedPath

A Multicenter Phenotype-Genotype Analysis of DM1 Patients in China

Conditions
Myotonic Dystrophy 1
Registration Number
NCT06101940
Lead Sponsor
Huashan Hospital
Brief Summary

Myotonic dystrophy 1 (DM1) is an autosomal, dominantly inherited neuromuscular disorder characterized by skeletal muscle weakness, myotonia, cardiac conduction abnormalities, cataracts, and other abnormalities. This disease results from an expansion of a cytosine-thymine-guanine (CTG) trinucleotide repeat in the 3'-untranslated region of the dystrophia myotonica protein kinase (DMPK) gene on chromosome 19. Currently, there is limited phenotype and genotype data available for DM1 patients with Chinese Han ethnicity. Therefore, this study aims to fill this gap and provide complementary data.

Detailed Description

This multicenter, prospective, observational study investigates the diagnosis and progression of Myotonic Dystrophy Type 1 (DM1) in Chinese patients through comprehensive data collection. The research protocol includes clinical assessments (strength evaluations, cognitive testing), diagnostic studies (genetic analysis, electromyography), imaging modalities (MRI, echocardiography, electrocardiography), functional evaluations (pulmonary function tests, posture and movement video analysis), and biological sampling (blood and muscle specimens). This integrated approach enables systematic characterization of DM1 manifestations across multiple organ systems, facilitating better understanding of disease progression patterns and potential biomarker identification in the Chinese population.

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Age between 18-80 years
  • With enough cognitivie ability to understand the content and sign the informed consent form
  • With CTG repeats >50 in DMPK gene, revealed by PCR test
Exclusion Criteria
  • Patients with severe mental illness, or severe anxiety and depression
  • With comorbidities such as traumatic brain injury and cranial tumors
  • A history of alcoholism, psychotropic substance abuse, etc.
  • Patients with severe medical conditions and unstable vital signs that cannot tolerate the tests.
  • Female in pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in 10 Metre Walk Test (10MWT)Baseline, Year 3, Year 5

The 10 Metre Walk Test is a performance measure used to assess walking speed in meters per second over a short distance. It can be employed to determine functional mobility, gait, and vestibular function

Secondary Outcome Measures
NameTimeMethod
Changes in ESS scaleBaseline, Year 3, Year 5

The Epworth Sleepiness Scale (ESS) measures the general level of daytime sleepiness. It is a subjective scale ranging from 0 to 24, asking the respondent to rate their propensity to doze off or fall asleep during eight common daily activities to assess the level of daytime sleepiness. A higher score on the ESS indicates a greater likelihood of daytime dozing.

Changes in FSS scaleBaseline, Year 3, Year 5

The Fatigue Severity Scale (FSS) is a method for evaluating the impact of fatigue on the participant. The FSS questionnaire contains nine statements that rate the severity of the participant's fatigue symptoms, ranging from 7 to 63. A higher score indicates more severe fatigue symptoms in the participant.

Changes in Video Hand Opening Time (vHOT)Baseline, Year 1, Year 3, Year 5

The Video Hand Opening Time (vHOT) is a quantitative assessment tool used to measure the time required for patients with myotonic dystrophy to fully open their hands after making a fist. This test evaluates myotonia severity by recording the duration from the initiation of hand opening to complete finger extension. The measurement is performed using video recording to ensure accurate timing. vHOT serves as an objective biomarker for assessing myotonic symptoms and monitoring disease progression in patients with myotonic dystrophy. A longer vHOT indicates more severe myotonia and greater functional impairment.

Trial Locations

Locations (1)

Huashan Hospital

🇨🇳

Shanghai, China

Huashan Hospital
🇨🇳Shanghai, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.